Quanterix published an application note exploring why measuring IL-17F alongside IL-17A may provide a more complete picture of the IL-17 pathway activity and therapeutic response in psoriasis.
Published
Signal category
Research & Knowledge
Quote
“Our latest application note explores why measuring IL-17F alongside IL-17A may provide a more complete picture of IL-17 pathway activity and therapeutic response.”
— Quanterix team
Company
Quanterix
Powering Biomarkers from Discovery to Diagnostics
- Industry
- Biotechnology Research
- Location
- Billerica, US
- Company size
- 509 employees
Quanterix is a global leader in precision biomarker science, making biology measurable to deliver earlier insights and support breakthroughs in disease research, diagnostics, and drug development. Its Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. Through the acquisition of Akoya Biosciences, Quanterix Spatial solutions deliver high-plex, quantitative protein analysis in tissue at single-cell resolution. Combined with Accelerator Laboratory services, Quanterix gives researchers the tools and expertise to translate discovery into precision diagnostics. Learn more at www.quanterix.com.
Founded 2007